Filing Flows › Voyager Therapeutics (VYGR) › Q2 2025
Voyager Therapeutics (VYGR) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 6, 2025
Voyager Therapeutics (VYGR) reported revenue of $5.2M for the second quarter 2025 (Q2 2025), -82% from a year earlier and -20% from the quarter before. Operating margin was -704.3%, net loss $33.4M (642.0% of revenue).
Voyager Therapeutics, Q2 2025: revenue $5.2M (-82% year over year), operating margin -704.3%, net loss $33.4M, operating cash flow −$33.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5.2M | -20% | -82% |
| Operating profit | −$36.6M | — | — |
| Net earnings | −$33.4M | — | — |
| Operating cash flow | −$33.3M | — | — |
What changed
Revenue was $5.2M in Q2 2025, down 82% year over year and down 20% from the previous quarter.
Operating costs exceeded revenue by $36.6M, an operating margin of -704.3%. Total costs fell 6% while revenue fell 82%. The quarter ended with a net loss of $33.4M, wider than the previous quarter's $31.0M loss.
Operating cash flow was −$33.3M. Non-cash charges added back $1.1M of depreciation and $4.1M of share-based compensation. Working capital and other items used $5.1M. Capital expenditures of $1.1M exceeded it, leaving free cash flow of −$34.4M.
Questions
What was Voyager Therapeutics' revenue in the second quarter 2025?
Voyager Therapeutics (VYGR) reported revenue of $5.2M for the second quarter 2025 (Q2 2025), -82% from a year earlier and -20% from the quarter before.
Was Voyager Therapeutics profitable in the second quarter 2025?
Operating loss was $36.6M (-704.3% of revenue) and net loss $33.4M.